Given that most invasive breast cancers are ER/PR+ HER2 −, developing and validating a subtype-specific risk model has proven challenging due to the need for very large prospective samples to achieve a reasonable number of TNBCs for model training and validation. This evidence concerns the gene ESR1 and invasive breast carcinoma.